Although faecal microbiota transplantation (FMT) has a well-established role in the treatment
of recurrent Clostridioides difficile infection (CDI), its widespread dissemination is limited by …

Fecal microbiota transplantation (FMT) is a well-established treatment for recurrent
Clostridioides difficile infection. FMT has become a more readily available and useful new …

Background Since 2013, several stool banks have been developed following publications
reporting on clinical success of 'faecal microbiota transplantation'(FMT) for recurrent …

Abstract In 2009 the first European Society of Clinical Microbiology and Infectious Diseases
(ESCMID) guideline for diagnosing Clostridium difficile infection (CDI) was launched. Since …

Background Clostridium difficile is the leading cause of antibiotic-associated diarrhoea, both
in healthcare facilities and in the community. The recurrence rate of C. difficile infection (CDI) …

Background Faecal microbiota transplantation (FMT) is an emerging treatment modality, but
its current clinical use and organisation are unknown. We aimed to describe the clinical use …

Metronidazole was until recently used as a first-line treatment for potentially life-threatening
Clostridioides difficile (CD) infection. Although cases of metronidazole resistance have been …

Background Faecal microbiota transplantation is an emerging therapeutic option,
particularly for the treatment of recurrent Clostridioides difficile infection. Stool banks that …

Fecal microbiota transplantation has proven to be an effective treatment for infections with
the gram-positive enteropathogen Clostridium difficile. Despite its effectiveness, the exact …

Clostridium difficile is an anaerobic bacillus that resides in the gut and has rapidly emerged
as a leading cause of antibiotic associated diarrheal disease in humans. The genetic basis …